These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16380251)

  • 1. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
    Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.
    Chackalamannil S; Xia Y; Greenlee WJ; Clasby M; Doller D; Tsai H; Asberom T; Czarniecki M; Ahn HS; Boykow G; Foster C; Agans-Fantuzzi J; Bryant M; Lau J; Chintala M
    J Med Chem; 2005 Sep; 48(19):5884-7. PubMed ID: 16161991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism-based identification of a potent thrombin receptor antagonist.
    Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee W; Kao G; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Smith-Torhan A; Alton K; Bryant M; Hsieh Y; Lau J; Palamanda J
    J Med Chem; 2007 Jan; 50(1):129-38. PubMed ID: 17201416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists.
    Chelliah MV; Chackalamannil S; Xia Y; Eagen K; Clasby MC; Gao X; Greenlee W; Ahn HS; Agans-Fantuzzi J; Boykow G; Hsieh Y; Bryant M; Palamanda J; Chan TM; Hesk D; Chintala M
    J Med Chem; 2007 Oct; 50(21):5147-60. PubMed ID: 17854166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of a new series of PAR1 antagonists.
    Planty B; Pujol C; Lamothe M; Maraval C; Horn C; Le Grand B; Perez M
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1735-9. PubMed ID: 20137929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo.
    Perez M; Lamothe M; Maraval C; Mirabel E; Loubat C; Planty B; Horn C; Michaux J; Marrot S; Letienne R; Pignier C; Bocquet A; Nadal-Wollbold F; Cussac D; de Vries L; Le Grand B
    J Med Chem; 2009 Oct; 52(19):5826-36. PubMed ID: 19791800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
    J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
    Curtin ML; Davidsen SK; Heyman HR; Garland RB; Sheppard GS; Florjancic AS; Xu L; Carrera GM; Steinman DH; Trautmann JA; Albert DH; Magoc TJ; Tapang P; Rhein DA; Conway RG; Luo G; Denissen JF; Marsh KC; Morgan DW; Summers JB
    J Med Chem; 1998 Jan; 41(1):74-95. PubMed ID: 9438024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thienopyrimidine-based P2Y12 platelet aggregation inhibitors.
    Kortum SW; Lachance RM; Schweitzer BA; Yalamanchili G; Rahman H; Ennis MD; Huff RM; TenBrink RE
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5919-23. PubMed ID: 19748783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of nor-seco himbacine analogs as thrombin receptor antagonists.
    Chelliah MV; Chackalamannil S; Xia Y; Eagen K; Greenlee WJ; Ahn HS; Agans-Fantuzzi J; Boykow G; Hsieh Y; Bryant M; Chan TM; Chintala M
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2544-9. PubMed ID: 22405832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 motif sequence: platelet aggregation and relaxant activities.
    Alexopoulos K; Fatseas P; Melissari E; Vlahakos D; Roumelioti P; Mavromoustakos T; Mihailescu S; Paredes-Carbajal MC; Mascher D; Matsoukas J
    J Med Chem; 2004 Jun; 47(13):3338-52. PubMed ID: 15189031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a vorapaxar analog with increased aqueous solubility.
    Xia Y; Chackalamannil S; Greenlee WJ; Wang Y; Hu Z; Root Y; Wong J; Kong J; Ahn HS; Boykow G; Hsieh Y; Kurowski S; Chintala M
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6676-9. PubMed ID: 20888225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1).
    Nantermet PG; Barrow JC; Lundell GF; Pellicore JM; Rittle KE; Young M; Freidinger RM; Connolly TM; Condra C; Karczewski J; Bednar RA; Gaul SL; Gould RJ; Prendergast K; Selnick HG
    Bioorg Med Chem Lett; 2002 Feb; 12(3):319-23. PubMed ID: 11814787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-protein-coupled receptors as signaling targets for antiplatelet therapy.
    Smyth SS; Woulfe DS; Weitz JI; Gachet C; Conley PB; Goodman SG; Roe MT; Kuliopulos A; Moliterno DJ; French PA; Steinhubl SR; Becker RC;
    Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):449-57. PubMed ID: 19023091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.
    Ueno H; Yokota K; Hoshi J; Yasue K; Hayashi M; Hase Y; Uchida I; Aisaka K; Katoh S; Cho H
    J Med Chem; 2005 May; 48(10):3586-604. PubMed ID: 15887966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SCH 530348: a novel oral thrombin receptor antagonist.
    Bonaca MP; Morrow DA
    Future Cardiol; 2009 Sep; 5(5):435-42. PubMed ID: 19715408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
    TRA*CER Executive and Steering Committees
    Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate.
    Yang XZ; Diao XJ; Yang WH; Li F; He GW; Gong GQ; Xu YG
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2089-92. PubMed ID: 23466230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic effects of the novel inhibitor of thrombin-induced offtelet aggregation and thrombus formation, 3-[2-[1,1':2',1"]-terphenyl-4'-yl)ethyl]phenoxyacetic acid.
    Miyamae T; Hashizume H; Ogawa T; Okayama T; Nukui E; Oshima K; Morikawa T; Hagiwara M
    Arzneimittelforschung; 1997 Jan; 47(1):13-8. PubMed ID: 9037437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
    Wu CC; Teng CM
    Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.